Research highlights increased cervical cancer risk in smokers, while ovarian tumors with BRCA2 mutations also commonly have BRCA1 mutations. A potential therapeutic approach for eliminating malignant urothelial cells is also explored through CD40 ligation.
A review highlights the association between excess body weight and increased cancer risk, particularly in colon, breast, endometrium, oesophagus, and kidney. The study suggests that alterations in hormone metabolism may play a role in this link, emphasizing the importance of weight management for cancer prevention.
Research identifies young women with breast cancer at increased risk of ovarian cancer, including those with BRCA1 and BRCA2 gene mutations. The study suggests that these women may benefit from prophylactic oophorectomy or counseling.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.
Researchers found that MMP-9 expression contributes to angiogenesis in human ovarian tumors, while dense breasts compromise diagnostic mammography sensitivity. Aspirin users have a lower risk of developing pancreatic cancer, according to the study.
A study found that hereditary BRCA1 and BRCA2 ovarian cancers have similar gene expression profiles to sporadic ovarian cancers. The research suggests shared molecular mechanisms between hereditary and sporadic ovarian carcinogenesis exist.
Women with irregular periods are at increased risk of developing osteoporosis later in life, according to a recent study. The research found that nearly all women with premature ovarian failure reported changes in their menstrual cycle, highlighting the importance of early evaluation and treatment.
Researchers found that women at high and elevated risk of ovarian cancer are less likely to get screened than those at lower risk. Most women overestimate their risk, with only 11% correctly estimating it.
A new study found that hormone replacement therapy, particularly estrogen alone, may increase the risk of epithelial ovarian cancer in postmenopausal women with an intact uterus. Women who used sequential progestins with estrogens had a higher risk of developing ovarian cancer compared to those who never used HRT.
Researchers found that thrombocytosis correlates with more aggressive ovarian cancer and poorer response to treatment. Patients with thrombocytosis had higher CA-125 levels, advanced stage disease, and greater tendency of cancer spread.
A commonly prescribed medication for treating endometriosis appears to elevate the risk of ovarian cancer, according to a new study. Women taking danazol were nearly three times more likely to develop ovarian cancer than those taking leuprolide, an anti-androgenic medication.
Research found that African-American women with ovarian cancer are at a 30% increased risk of death from any cause compared to Caucasian women. The study also revealed significant differences in tumor stage, lymph node involvement, and surgery rates between the two ethnic groups. Median survival times were also shorter for African-Amer...
A study at Memorial Sloan Kettering Cancer Center found that BRCA mutation carriers are more likely to be diagnosed with early-stage breast and ovarian cancers. The research showed that intensive screening and preventive surgery can lead to the detection of these cancers, but also highlights the limitations of screening.
A new computer-based algorithm identifies a distinct proteomic pattern that distinguishes malignant from benign tumours within the ovary with 100% sensitivity and 95% specificity. This technique may help screen for ovarian cancer in high-risk and general populations.
A study led by Joellen Schildkraut at Duke University Medical Center found that oral contraceptives with higher levels of progestin may be more protective against ovarian cancer than those with lower progestin potency. Higher progestin levels were associated with a significant reduction in risk, even for short periods of use.
A new study analyzing oral contraceptive use among women with epithelial ovarian cancer found a significant association between progestin levels and reduced risk. Women using low-progestin/high-estrogen contraceptives were more likely to develop ovarian cancer compared to those using high-progestin/high-estrogen contraceptives.
UK researchers have made significant progress in preserving fertility for women with cancer by grafting ovarian tissue from cancer patients into mice, demonstrating safety and feasibility. The study has raised hopes for women who require immediate treatment or lack a partner, offering an alternative to embryo freezing.
Researchers found that Raloxifene stimulated the growth of ovarian cancer cell lines, raising concerns about its use in ER+ patients. The study advises caution when prescribing Raloxifene to women with a history of breast cancer and ovarian cancer.
Scientists have found that teenage girls with Turner's syndrome still possess follicles in their ovaries, which may enable them to produce eggs. This breakthrough discovery provides a glimmer of hope for these women who are usually infertile due to the syndrome. Further research is needed to confirm the findings and explore the possibi...
Researchers found that raloxifene stimulates cell growth in ovarian adenocarcinoma cells with estrogen receptors, increasing the risk of recurrence. The study suggests caution for women with a history of breast cancer and estrogen receptor-positive ovarian cancer.
Researchers have successfully used frozen ovarian tissue to induce live births in large mammals, including lambs. The study offers a promising solution for women who become infertile due to cancer treatments, providing an alternative to traditional fertility preservation methods.
A new platinum-based cancer drug, BBR3464, has shown promising activity against ovarian cancer that is resistant to cisplatin. The drug, developed by Nicholas Farrell and his team, has been found to be significantly more potent than cisplatin and may offer new hope for the treatment of this devastating disease.
Researchers at the University of Pittsburgh Medical Center found that low-dose oral contraceptives offer a 40% reduced risk of ovarian cancer, similar to high-dose pills. The protection begins soon after use and continues for at least 30 years after stopping.
A new vaccine has shown promise in boosting immune responses against HER-2/neu protein in patients with breast and ovarian cancer. Researchers have identified a key protein fragment that can trigger an immune response, leading to sustained detectable immunity up to two years after vaccination.
The data from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer indicates that the vaccine induces a positive immunological response, as measured by a delayed type hypersensitivity test. Favorable clinical responses were also observed, including complete regression of tumors and normalization of CA-125 levels.
Researchers have reported promising results from a Phase I-II trial of an ovarian cancer vaccine made from patient's own cancer cells. Eight of 10 patients showed immunological response, with one experiencing complete tumor disappearance and CA125 levels normalization.
Researchers have identified three recurrent BRCA1 mutations in Polish breast-ovarian cancer families, suggesting founder mutations. These mutations, 5382insC, C61G, and 4153delA, account for 82% of the study's findings, enabling more efficient screening and diagnosis.
Three Cedars-Sinai physicians are leading a fight against women's cancers through innovative research, clinical care, and genetic screenings. Beth Karlan focuses on curing and preventing ovarian cancer, while Maren Scheuner develops personalized prevention plans for breast, endometrial, and ovarian cancers.
A Northwestern University researcher is leading a five-year, $5 million National Cancer Institute-sponsored study to improve current methods and evaluate new tests for detecting early-stage ovarian cancer. The study aims to identify novel biomarkers that can detect ovarian cancer in its early stages.
A new ovarian tumor index helps physicians accurately diagnose ovarian tumors as either cancerous or benign. The index uses real-time ultrasound findings, patient age, and other characteristics to provide a valuable way for clinicians to plan further testing, surgery, or other clinical management.
Researchers at Fox Chase Cancer Center are conducting a clinical trial to investigate the efficacy of fenretinide, a vitamin A-related medicine, in preventing ovarian cancer. Women with high-risk factors for breast and ovarian cancer will take part in this study to examine the molecular effects of fenretinide on ovarian tissue.
A five-year clinical trial found that premenopausal women taking fenretinide had a lower risk of developing another breast cancer, while postmenopausal women showed no significant benefit. The study also detected a reduced risk of ovarian cancer in younger women treated with fenretinide.
The Pacific Ovarian Cancer Research Consortium aims to discover genes, develop a cancer vaccine, and improve treatment outcomes for ovarian cancer. The five-year study will involve researchers from several institutions and involve at least 3,500 women in its various studies.
A study suggests that an imbalance in genes expressed on the X chromosome may lead to ovarian cancer development. The research found nonrandom X-chromosome inactivation in over 50% of women with invasive ovarian cancer, particularly those with BRCA1 mutations.
A gene knockout study has found that inactivating the Bax gene in female mice sustains ovarian function into advanced age. The research reveals that aged Bax-deficient mice maintain hundreds of ovarian follicles with functioning cells but are unable to ovulate or become pregnant.
Measuring the levels of inhibin-a and inhibin-b in older women shows a more sensitive test for reproductive potential compared to FSH. The research found that inhibin levels drop as women approach menopause, indicating a direct measure of ovarian function.
Researchers found that progestin activates apoptosis in the ovarian lining, preventing precancerous cells from becoming malignant. The study suggests that periodically administering progestin could be a highly effective preventive treatment for ovarian cancer.
A multi-center study provides clear guidelines for genetic testing in women with breast cancer, identifying those at high risk of ovarian cancer. The study found that nearly 40% of participants had abnormalities in BRCA1 and BRCA2 genes, associated with a 10-fold increase in ovarian cancer risk.
Researchers at Thomas Jefferson University have created an autologous ovarian cancer vaccine that stimulates an immune response in patients, showing promise for treatment. The vaccine is custom-made for each patient and has been safe with no significant side effects, paving the way for further clinical trials.
Researchers found a strong link between increased ovulatory cycles and p53 genetic mutations in ovarian cancer. Women at high risk can protect themselves by reducing their ovulation through birth control, pregnancy, or breast-feeding.